Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis

Arthritis and Rheumatology

Volumn 66, Issue 2, 2014, Pages 407-417

  Sobanski, Vincent ^a   Dauchet, Luc ^b   Lefèvre, Guillaume ^a   Lambert, Marc ^a   Morell Dubois, Sandrine ^a   Sy, Thierno ^a   Hachulla, Eric ^a   Hatron, Pierre Yves ^a   Launay, David ^a   Dubucquoi, Sylvain ^b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DIRECTED RNA POLYMERASE III ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; EMBASE; ENVIRONMENTAL FACTOR; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; SEROPREVALENCE; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC;

EID: 84896266385     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38219     Document Type: Article

References (52)

1. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010;6: 112-6.
2. Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 1993;91: 1399-404.
3. Okano Y, Steen VD, Medsger TA Jr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993;119: 1005-13.
4. Kuwana M, Kimura K, Kawakami Y. Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay. Arthritis Rheum 2002;46: 2742-7.
5. Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 2005;52: 2425-32.
6. Bardoni A, Rossi P, Salvini R, Bobbio-Pallavicini F, Caporali R, Montecucco C. Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis. Clin Exp Rheumatol 2003;21: 301-6.
7. Ceribelli A, Krzyszczak ME, Li Y, Ross SJ, Chan JY, Chan EK, et al. Atypical clinical presentation of a subset of patients with anti-RNA polymerase III: non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining. Arthritis Res Ther 2011;13:R119.
8. Airo P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011;38: 1329-34.
9. Maes L, Blockmans D, Verschueren P, Westhovens R, De Beeck KO, Vermeersch P, et al. Anti-PM/Scl-100 and anti-RNApolymerase III antibodies in scleroderma. Clin Chim Acta 2010; 411: 965-71.
10. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a crosssectional analysis of data from an Australian cohort. Arthritis Res Ther 2011;13:R211.
11. Kang EH, Lee EB, Kim DJ, Im CH, Lee HJ, Song YW. Anti-RNA polymerase antibodies in Korean patients with systemic sclerosis and their association with clinical features. Clin Exp Rheumatol 2005;23: 731-2.
12. Emilie S, Goulvestre C, Berezne A, Pagnoux C, Guillevin L, Mouthon L. Anti-RNA polymerase III antibodies are associated with scleroderma renal crisis in a French cohort. Scand J Rheumatol 2011;40: 404-6.
13. Chang M, Wang RJ, Yangco DT, Sharp GC, Komatireddy GR, Hoffman RW. Analysis of autoantibodies against RNA polymerases using immunoaffinity-purified RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay. Clin Immunol Immunopathol 1998;89: 71-8.
14. Faucher B, Stein P, Granel B, Weiller PJ, Disdier P, Serratrice J, et al. Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma. Eur J Intern Med 2010;21: 114-7.
15. Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, et al. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology (Oxford) 2009;48: 1570-4.
16. Parker JC, Burlingame RW, Webb TT, Bunn CC. Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA. Rheumatology (Oxford) 2008;47: 976-9.
17. Harvey GR, Rands AL, McHugh NJ. Anti-RNA polymerase antibodies in systemic sclerosis (SSc): association with antitopoisomerase I antibodies and identification of autoreactive subunits of RNA polymerase II. Clin Exp Immunol 1996;105: 468-74.
18. Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013;12: 340-54.
19. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35: 35-42.
20. Hudson M, Fritzler MJ, Baron M. Systemic sclerosis: establishing diagnostic criteria. Medicine (Baltimore) 2010;89: 159-65.
21. Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001;28: 2454-9.
22. Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007;34: 104-9.
23. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23: 581-90.
24. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28: 1573-6.
25. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007;100: 485-94.
26. Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
27. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-36.
28. QUADAS-2 manual. Bristol (UK): University of Bristol; 2011. URL: http://www.bris.ac.uk/quadas/quadas-2/.
29. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Software 2010;36: 1-48.
30. Agarwal SK, Gourh P, Shete S, Paz G, Divecha D, Reveille JD, et al. Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis. J Rheumatol 2009;36: 2715-23.
31. Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K, et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 2008;158: 487-95.
32. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003;42: 534-40.
33. Johnson SR, Fransen J, Khanna D, Baron M, van den Hoogen F, Medsger TA Jr, et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 2012;64: 358-67.
34. Low AH, Wong S, Thumboo J, Ng SC, Fong KY. Comparison of a new line immunoassay with conventional methods for the detection of systemic sclerosis-specific autoantibodies in an Asian systemic sclerosis cohort [abstract]. Int J Rheum Dis 2010;13 Suppl 1: 184-5.
35. Majone F, Olivieri S, Cozzi F, Montaldi A, Tonello M, Visentin MS, et al. Increased apoptosis in circulating lymphocyte cultures of anti-RNA polymerase III positive patients with systemic sclerosis. Rheumatol Int 2009;29: 891-5.
36. Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011;13:R172.
37. Morozzi G, Bellisai F, Fineschi I, Scaccia F, Pucci G, Simpatico A, et al. Prevalence of anti-histone antibodies, their clinical significance and correlation with other autoantibodies in a cohort of Italian scleroderma patients. Autoimmun Highlights 2011;2: 29-33.
38. Muller Cde S, Paiva Edos S, Azevedo VF, Radominski SC, Lima Filho JH. Autoantibody profile and clinical correlation in a group of patients with systemic sclerosis in southern Brazil. Rev Bras Reumatol 2011;51:314-8, 323-4.
39. Ogawa F, Shimizu K, Hara T, Muroi E, Komura K, Takenaka M, et al. Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage. Arch Dermatol Res 2010;302: 27-35.
40. Rodriguez-Reyna TS, Hinojosa-Azaola A, Martinez-Reyes C, Nunez-Alvarez CA, Torrico-Lavayen R, Garcia-Hernandez JL, et al. Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients. Autoimmunity 2011;44: 576-84.
41. Van Praet JT, Van Steendam K, Smith V, De Bruyne G, Mimori T, Bonroy C, et al. Specific anti-nuclear antibodies in systemic sclerosis patients with and without skin involvement: an extended methodological approach. Rheumatology (Oxford) 2011;50: 1302-9.
42. Wang Q, Xu D, Li MT, Hou Y, Zhao JL, Zeng XF. The clinical significance of scleroderma-related autoantibodies in Chinese systemic sclerosis patients: reports from a prospective registry database [abstract]. Int J Rheum Dis 2010;13 Suppl 1:186.
43. Ziswiler HR, Urech R, Balmer J, Ostensen M, Mierau R, Villiger PM. Clinical diagnosis compared to classification criteria in a cohort of 54 patients with systemic sclerosis and associated disorders. Swiss Med Wkly 2007;137: 586-90.
44. Koenig M, Dieude M, Senecal JL. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008;7: 588-93.
45. Reveille JD, Solomon DH, and the American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003;49: 399-412.
46. Walker UA, Tyndall A, Czirjak L, Denton CP, Farge-Bancel D, Kowal-Bielecka O, et al, and the EUSTAR co-authors. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 2009;68: 856-62.
47. Kuwana M, Okano Y, Kaburaki J, Tojo T, Medsger TA Jr. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum 1994;37: 902-6.
48. McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007;57: 318-26.
49. Kuwana M, Pandey JP, Silver RM, Kawakami Y, Kaburaki J. HLA class II alleles in systemic sclerosis patients with anti-RNA polymerase I/III antibody: associations with subunit reactivities. J Rheumatol 2003;30: 2392-7.
50. Liu X, Mayes MD, Tan FK, Wu M, Reveille JD, Harper BE, et al. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum 2013;65: 226-35.
51. Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 2012;64: 2986-94.
52. Gelber AC, Manno RL, Shah AA, Woods A, Le EN, Boin F, et al. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. Medicine (Baltimore) 2013;92: 191-205.